Floatz logo

2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-

Recurrent Childhood Rhabdomyosarcoma

National Cancer Institute (NCI)Small moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

58 Active assets in the Recurrent Childhood Rhabdomyosarcoma cohort.

Asset / SponsorPhaseRating
Irinotecan
Eisai Inc.
Phase 2BBB
Ipilimumab
Children's National Research Institute
Phase 2BB
Irinotecan
Milton S. Hershey Medical Center
Phase 2BB
CALCIUM PHOSPHATE
Children's Oncology Group
Phase 3BB
Eloxatin
National Cancer Institute (NCI)
Phase 2BB

View all 50 →

Same molecule, other indications

2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)- is also rated in:

acute monocytic leukemiaDormant
BBB
Indicative ·
74 / 100
View asset →
acute megakaryoblastic leukemiaDormant
BBB
Indicative ·
72 / 100
View asset →
acute myeloid leukemia with minimal differentiationDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →